Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Bevacizumab + Chemo in Advanced Lung Adenocarcinoma
NCT05675033Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of serplulimab in lung adenocarcinoma, sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
serplulimab
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT05675033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675033.